Nycomed and VHA sign five-year deal
Nycomed has secured a five-year agreement with VHA, the nation's largest health-care network,to provide its nonionic imaging agent Omnipaque (iohexol) underthe VHA Plus label. It is the second such contract signed recently by Nycomed andVHA. In October
Nycomed has secured a five-year agreement with VHA, the nation's largest health-care network,to provide its nonionic imaging agent Omnipaque (iohexol) underthe VHA Plus label.
It is the second such contract signed recently by Nycomed andVHA. In October 1994, the companies agreed to a three-year pactpermitting VHA Plus labeling of Omniscan (gadodiamide), a nonionicMRI imaging agent.
The private labeling deal permits VHA to market the agentsto its network of 1132 health-care organizations, which representnearly one of five U.S. hospitals. The network purchases $6 billionworth of supplies and services annually through VHA contracts,Nycomed officials said.
New MRI Research Explores Links Between Waist-to-Hip Ratio and Memory in Aging
March 13th 2025Researchers found that a higher waist-to-hip ratio in midlife was associated with higher mean diffusivity in 26 percent of total white matter tracts in the cingulum as well as the superior and inferior longitudinal fasciculus.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.
